My Watchlist Items

      No Watchlist
Array ( [0] => stdClass Object ( [symbol] => CYTR [price] => 3.2101 [beta] => 2.086596 [volAvg] => 228104 [mktCap] => 117104448 [lastDiv] => 0 [range] => 0.39-5.0 [changes] => 0.2401 [companyName] => CytRx Corporation [currency] => USD [cik] => 0000799698 [isin] => US2328286081 [cusip] => 232828608 [exchange] => Nasdaq Capital Market [exchangeShortName] => NASDAQ [industry] => Biotechnology [website] => http://www.cytrx.com [description] => CytRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. The company is headquartered in Los Angeles, California and currently employs 6 full-time employees. The firm is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. The company is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy. The company is also involved in evaluating aldoxorubicin in a Phase IIb clinical trial in small cell lung cancer; a Phase II clinical trial in human immunodeficiency virus-related Kaposi's sarcoma; a Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); a Phase Ib trial in combination with ifosfamide in patients with STS, and a Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. The company is engaged in the pre-clinical development for DK049, an anti-cancer drug conjugate that utilizes its Linker Activated Drug Release (LADR) technology. [ceo] => Mr. Steven Kriegsman [sector] => Healthcare [country] => US [fullTimeEmployees] => 4 [phone] => 13108265648 [address] => 11726 San Vicente Blvd Ste 650 [city] => Los Angeles [state] => CALIFORNIA [zip] => 90049 [dcfDiff] => -0.43 [dcf] => 3.2467 [image] => https://financialmodelingprep.com/image-stock/CYTR.jpg [ipoDate] => 1986-11-10 [defaultImage] => 1 [isEtf] => [isActivelyTrading] => 1 ) )
CytRx Corporation (CYTR)
   3.2101   0.2401(+8.08%)
CytRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. The company is headquartered in Los Angeles, California and currently employs 6 full-time employees. The firm is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. The company is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy. The company is also involved in evaluating aldoxorubicin in a Phase IIb clinical trial in small cell lung cancer; a Phase II clinical trial in human immunodeficiency virus-related Kaposi's sarcoma; a Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); a Phase Ib trial in combination with ifosfamide in patients with STS, and a Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. The company is engaged in the pre-clinical development for DK049, an anti-cancer drug conjugate that utilizes its Linker Activated Drug Release (LADR) technology.
TitleNamePayCurrency PayGenderYear BornTitle Since
Senior Vice President, Drug Devel. Dr. Felix Kratz Ph.D. N/A USD N/A N/A
Chief Bus. Officer Terri Stevens N/A USD N/A N/A
Pres of USA and Head of Launch & Commercial Operations Ms. Molly Painter N/A USD female N/A N/A
Global & U.S. Head of Corporation Communications Molly Carey Poarch N/A USD N/A N/A
Chief Financial Officer & Treasurer Mr. John Y. Caloz 500000 USD male 1952 N/A
Chairman & Chief Executive Officer Mr. Steven A. Kriegsman 1050000 USD male 1942 N/A
SymbolDateRatingRating Score Rating Details
CYTR 11 June, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
CYTR 10 June, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
CYTR 9 June, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
CYTR 8 June, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
CYTR 7 June, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
CYTR 4 June, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
CYTR 3 June, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
CYTR 2 June, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
CYTR 1 June, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
CYTR 28 May, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
CYTR 27 May, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
CYTR 26 May, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
CYTR 25 May, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
CYTR 24 May, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
CYTR 21 May, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
CYTR 20 May, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
CYTR 19 May, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
CYTR 18 May, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
CYTR 17 May, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
CYTR 14 May, 2021 B+ 4 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Strong Buy)
CYTR 13 May, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 12 May, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 11 May, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 10 May, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 7 May, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 6 May, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 5 May, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 4 May, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 3 May, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 30 April, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 29 April, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 28 April, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 27 April, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 26 April, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 23 April, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 22 April, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 21 April, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 20 April, 2021 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 10 January, 2020 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 9 January, 2020 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 8 January, 2020 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 7 January, 2020 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 6 January, 2020 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 3 January, 2020 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 2 January, 2020 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 1 January, 2020 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 31 December, 2019 B 3 Rating DCF: (Strong Buy)
Rating ROE: (Sell)
Rating DCF: (Sell)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 30 December, 2019 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 27 December, 2019 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 26 December, 2019 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 25 December, 2019 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 24 December, 2019 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 23 December, 2019 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 20 December, 2019 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 19 December, 2019 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 18 December, 2019 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 17 December, 2019 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 16 December, 2019 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 13 December, 2019 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 12 December, 2019 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 11 December, 2019 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 10 December, 2019 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 9 December, 2019 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 6 December, 2019 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 5 December, 2019 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 4 December, 2019 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 3 December, 2019 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 2 December, 2019 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 29 November, 2019 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 28 November, 2019 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 27 November, 2019 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 26 November, 2019 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 25 November, 2019 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 22 November, 2019 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 21 November, 2019 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 20 November, 2019 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 19 November, 2019 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 18 November, 2019 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 15 November, 2019 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 14 November, 2019 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 13 November, 2019 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 12 November, 2019 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 11 November, 2019 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 8 November, 2019 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 7 November, 2019 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 6 November, 2019 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 5 November, 2019 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 4 November, 2019 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 1 November, 2019 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 31 October, 2019 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 30 October, 2019 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 29 October, 2019 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 28 October, 2019 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 25 October, 2019 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 24 October, 2019 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 23 October, 2019 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 22 October, 2019 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 21 October, 2019 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 18 October, 2019 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
CYTR 17 October, 2019 B+ 3 Rating DCF: (Strong Buy)
Rating ROE: (Neutral)
Rating DCF: (Neutral)
Rating DE: (Neutral)
Rating PE: (Strong Sell)
Rating PB: (Buy)
HolderSharesDate ReportedWeight Percent
SOROS FUND MANAGEMENT LLC 81800 15 May, 2014 N/A
SymbolTransaction DateReporting CikSecurities Owned Company CikReporting NameAcquistion Or DispositionForm Type Securities TransactedSecurity NameLink
CYTR 14 August, 2020 0001690913 590247 0000799698 Brien Earl W A 4 150000 Common Stock, par value $0.001 per share View
CYTR 14 August, 2020 0001690913 300000 0000799698 Brien Earl W D 4 150000 Stock Option (right to buy) View
CYTR 7 August, 2020 0001715463 335373 0000799698 Caldwell Joel K D 4 174627 Common Stock, par value $0.001 per share View
CYTR 7 August, 2020 0001715463 510000 0000799698 Caldwell Joel K A 4 450000 Common Stock, par value $0.001 per share View
CYTR 7 August, 2020 0001715463 0 0000799698 Caldwell Joel K D 4 450000 Stock Option (right to buy) View
CYTR 7 August, 2020 0001252440 600785 0000799698 IGNARRO LOUIS D 4 271642 Common Stock, par value $0.001 per share View
CYTR 7 August, 2020 0001252440 872427 0000799698 IGNARRO LOUIS A 4 700000 Common Stock, par value $0.001 per share View
CYTR 7 August, 2020 0001252440 0 0000799698 IGNARRO LOUIS D 4 700000 Stock Option (right to buy) View
CYTR 7 August, 2020 0001197482 3668038 0000799698 KRIEGSMAN STEVEN A D 4 1164179 Common Stock, par value $0.001 per share View
CYTR 7 August, 2020 0001197482 4832217 0000799698 KRIEGSMAN STEVEN A A 4 3000000 Common Stock, par value $0.001 per share View
CYTR 7 August, 2020 0001197482 0 0000799698 KRIEGSMAN STEVEN A D 4 3000000 Stock Option (right to buy) View
CYTR 13 December, 2019 0001715463 450000 0000799698 Caldwell Joel K A 4 450000 Stock Options (right to buy) View
CYTR 13 December, 2019 0001690913 450000 0000799698 Brien Earl W A 4 450000 Stock option (right to buy) View
CYTR 13 December, 2019 0001252440 700000 0000799698 IGNARRO LOUIS A 4 700000 Stock Option (right to buy) View
CYTR 13 December, 2019 0001197482 3000000 0000799698 KRIEGSMAN STEVEN A A 4 3000000 Stock Option (right to buy) View
CYTR 13 December, 2019 0001243975 350000 0000799698 CALOZ JOHN Y A 4 350000 Stock Option (right to buy) View
CYTR 15 December, 2017 0001715463 30000 0000799698 Caldwell Joel K A 4 30000 Stock Options (right to buy) View
CYTR 15 December, 2017 0001690913 70000 0000799698 Brien Earl W A 4 70000 Stock option (right to buy) View
CYTR 15 December, 2017 0001252440 30000 0000799698 IGNARRO LOUIS A 4 30000 Stock Option (right to buy) View
CYTR 15 December, 2017 0001197482 208334 0000799698 KRIEGSMAN STEVEN A A 4 208334 Stock Option (right to buy) View
CYTR 15 December, 2017 0001197482 387597 0000799698 KRIEGSMAN STEVEN A A 4 387597 CytRx Common Stock View
CYTR 15 December, 2017 0001243975 58334 0000799698 CALOZ JOHN Y A 4 58334 Stock Option (right to buy) View
CYTR 15 December, 2017 0001726224 25000 0000799698 Kratz Felix A 4 25000 Stock Option (right to buy) View
CYTR 12 July, 2017 0001715463 180000 0000799698 Caldwell Joel K A 4 180000 Stock Options (right to buy) View
CYTR 15 December, 2016 0001690913 180000 0000799698 Brien Earl W A 4 180000 Stock Option (right to buy) View
CYTR 15 December, 2016 0001636273 180000 0000799698 Chawla Anita J A 4 180000 Stock Option (right to buy) View
CYTR 15 December, 2016 0001252440 180000 0000799698 IGNARRO LOUIS A 4 180000 Stock Option (right to buy) View
CYTR 15 December, 2016 0001033369 180000 0000799698 RUBINFELD JOSEPH A 4 180000 Stock Option (right to buy) View
CYTR 15 December, 2016 0001197482 2325581 0000799698 KRIEGSMAN STEVEN A A 4 2325581 Common Stock View
CYTR 15 December, 2016 0001197482 1250000 0000799698 KRIEGSMAN STEVEN A A 4 1250000 Stock Option (right to buy) View
CYTR 15 December, 2016 0001243975 350000 0000799698 CALOZ JOHN Y A 4 350000 Stock Option (right to buy) View
CYTR 15 December, 2016 0001278711 400000 0000799698 LEVITT DANIEL J A 4 400000 Stock Option (right to buy) View
CYTR 15 December, 2016 0001450614 150000 0000799698 Wieland Douglas Scott A 4 150000 Stock Option (right to buy) View
CYTR 2 December, 2016 0001690913 180000 0000799698 Brien Earl W A 4 180000 Stock options (right to buy) View
CYTR 11 January, 2016 0001663771 350000 0000799698 Ware Olivia C A 4 350000 Stock option (right to buy) View
CYTR 15 December, 2015 0001640850 180000 0000799698 SELTER ERIC JAY A 4 180000 Stock Option (right to buy) View
CYTR 15 December, 2015 0001636273 180000 0000799698 Chawla Anita J A 4 180000 Stock Option (right to buy) View
CYTR 15 December, 2015 0001529371 180000 0000799698 Cohen Cheryl A 4 180000 Stock Option (right to buy) View
CYTR 15 December, 2015 0001267476 180000 0000799698 Wennekamp Richard L. A 4 180000 Stock Option (right to buy) View
CYTR 15 December, 2015 0001252440 180000 0000799698 IGNARRO LOUIS A 4 180000 Stock Option (right to buy) View
CYTR 15 December, 2015 0001033369 180000 0000799698 RUBINFELD JOSEPH A 4 180000 Stock Option (right to buy) View
CYTR 15 December, 2015 0001197482 1000000 0000799698 KRIEGSMAN STEVEN A A 4 1000000 Stock Option (right to buy) View
CYTR 15 December, 2015 0001243975 300000 0000799698 CALOZ JOHN Y A 4 300000 Stock Option (right to buy) View
CYTR 15 December, 2015 0001278711 500000 0000799698 LEVITT DANIEL J A 4 500000 Stock Option (right to buy) View
CYTR 15 December, 2015 0001297707 300000 0000799698 Levin Ben A 4 300000 Stock Option (right to buy) View
CYTR 15 December, 2015 0001450614 100000 0000799698 Wieland Douglas Scott A 4 100000 Stock Option (right to buy) View
CYTR 15 December, 2014 0001252440 180000 0000799698 IGNARRO LOUIS A 4 180000 Stock Option (right to buy View
CYTR 15 December, 2014 0001033369 180000 0000799698 RUBINFELD JOSEPH A 4 180000 Stock Option (right to buy) View
CYTR 15 December, 2014 0001197482 600000 0000799698 KRIEGSMAN STEVEN A A 4 600000 Stock Option (right to buy) View
CYTR 15 December, 2014 0001243975 200000 0000799698 CALOZ JOHN Y A 4 200000 Stock Option View
CYTR 15 December, 2014 0001278711 400000 0000799698 LEVITT DANIEL J A 4 400000 Stock Option View
CYTR 15 December, 2014 0001297707 200000 0000799698 Levin Ben A 4 200000 Stock Option (right to buy) View
CYTR 15 December, 2014 0001450614 200000 0000799698 Wieland Douglas Scott A 4 200000 Stock Option (right to buy) View
CYTR 1 January, 2014 0001278711 214286 0000799698 LEVITT DANIEL J A 4 100000 Common Stock View
CYTR 1 January, 2014 0001278711 157706 0000799698 LEVITT DANIEL J A 4/A 100000 Common Stock View
CYTR 1 January, 2014 0001278711 157983 0000799698 LEVITT DANIEL J A 4/A 100000 Common Stock View
CYTR 1 January, 2014 0001278711 161036 0000799698 LEVITT DANIEL J A 4/A 100000 Common Stock View
CYTR 10 December, 2013 0001550653 4577605 0000799698 Patterson Scott Bradford D 4 334979 CYTR Common Stock, $0.01 par value per share View
CYTR 10 December, 2013 0001267477 180000 0000799698 SELTER MARVIN R A 4 180000 Stock Option (right to buy) View
CYTR 10 December, 2013 0001267477 0 0000799698 SELTER MARVIN R D 4 180000 Stock Option (right to buy) View
CYTR 10 December, 2013 0001267476 180000 0000799698 Wennekamp Richard L. A 4 180000 Stock Option (right to buy) View
CYTR 10 December, 2013 0001252440 180000 0000799698 IGNARRO LOUIS A 4 180000 Stock Option (right to buy) View
CYTR 10 December, 2013 0001050944 180000 0000799698 LINK MAX A 4 180000 Stock Option (right to buy) View
CYTR 10 December, 2013 0001033369 180000 0000799698 RUBINFELD JOSEPH A 4 180000 Stock Option (right to buy) View
CYTR 10 December, 2013 0001197482 925000 0000799698 KRIEGSMAN STEVEN A A 4 925000 Stock Option (right to buy) View
CYTR 10 December, 2013 0001243975 150000 0000799698 CALOZ JOHN Y A 4 150000 Stock Option (right to buy) View
CYTR 10 December, 2013 0001278711 500000 0000799698 LEVITT DANIEL J A 4 500000 Stock Option (right to buy) View
CYTR 10 December, 2013 0001297707 300000 0000799698 Levin Ben A 4 300000 Stock Option (right to buy) View
CYTR 10 December, 2013 0001450614 150000 0000799698 Wieland Douglas Scott A 4 150000 Stock Option (right to buy) View
CYTR 3 December, 2013 0001550653 4912584 0000799698 Patterson Scott Bradford A 4 42131 CYTR Common Stock, $0.01 par value per share View
CYTR 2 December, 2013 0001550653 4870453 0000799698 Patterson Scott Bradford A 4 77148 CYTR Common Stock, $0.01 par value per share View
CYTR 29 November, 2013 0001550653 4793305 0000799698 Patterson Scott Bradford A 4 165700 CYTR Common Stock, $0.01 par value per share View
CYTR 7 November, 2013 0001550653 4627605 0000799698 Patterson Scott Bradford A 4 50000 CYTR Common Stock, $0.01 par value per share View
CYTR 1 April, 2013 0001550653 4577605 0000799698 Patterson Scott Bradford A 4 4083 CYTR Common Stock, $0.01 par value per share View
CYTR 20 March, 2013 0001550653 4569542 0000799698 Patterson Scott Bradford A 4 8420 CYTR Common Stock, $0.01 par value per share View
CYTR 20 March, 2013 0001550653 4573522 0000799698 Patterson Scott Bradford A 4 3980 CYTR Common Stock, $0.01 par value per share View
CYTR 19 March, 2013 0001550653 4561122 0000799698 Patterson Scott Bradford A 4 24100 CYTR Common Stock, $0.01 par value per share View
CYTR 18 March, 2013 0001550653 4537022 0000799698 Patterson Scott Bradford A 4 3000 CYTR Common Stock, $0.01 par value per share View
CYTR 13 March, 2013 0001550653 4534022 0000799698 Patterson Scott Bradford A 4 360 CYTR Common Stock, $0.01 par value per share View
CYTR 11 March, 2013 0001550653 4533662 0000799698 Patterson Scott Bradford A 4 55000 CYTR Common Stock, $0.01 par value per share View
CYTR 8 March, 2013 0001197482 74176 0000799698 KRIEGSMAN STEVEN A A 4 74176 Stock Option (right to buy) View
CYTR 31 December, 2012 0001278711 200000 0000799698 LEVITT DANIEL J A 4 100000 Common Stock View
CYTR 31 December, 2012 0001278711 114286 0000799698 LEVITT DANIEL J A 4/A 100000 Common Stock View
CYTR 10 December, 2012 0001033369 100000 0000799698 RUBINFELD JOSEPH A 4 100000 Stock Option (right to buy) View
CYTR 10 December, 2012 0001267477 100000 0000799698 SELTER MARVIN R A 4 100000 Stock Option (right to buy) View
CYTR 10 December, 2012 0001267477 0 0000799698 SELTER MARVIN R D 4 100000 Stock Option (right to buy) View
CYTR 10 December, 2012 0001267476 100000 0000799698 Wennekamp Richard L. A 4 100000 Stock Option (right to buy) View
CYTR 10 December, 2012 0001252440 100000 0000799698 IGNARRO LOUIS A 4 100000 Stock Option (right to buy) View
CYTR 10 December, 2012 0001050944 100000 0000799698 LINK MAX A 4 100000 Stock Option (right to buy) View
CYTR 10 December, 2012 0001197482 500000 0000799698 KRIEGSMAN STEVEN A A 4 500000 Stock Option (right to buy) View
CYTR 10 December, 2012 0001243975 100000 0000799698 CALOZ JOHN Y A 4 100000 Stock Option (right to buy) View
CYTR 10 December, 2012 0001297707 100000 0000799698 Levin Ben A 4 100000 Stock Option (right to buy) View
CYTR 10 December, 2012 0001450614 100000 0000799698 Wieland Douglas Scott A 4 100000 Stock Option(right to buy) View
CYTR 10 December, 2012 0001033369 30000 0000799698 RUBINFELD JOSEPH A 4 30000 Stock Option (right to buy) View
CYTR 22 October, 2012 0001550653 4478662 0000799698 Patterson Scott Bradford A 4 115000 CYTR Common Stock, $0.01 par value per share View
CYTR 19 October, 2012 0001550653 4363662 0000799698 Patterson Scott Bradford A 4 65000 CYTR Common Stock, $0.01 par value per share View
CYTR 18 October, 2012 0001550653 4298662 0000799698 Patterson Scott Bradford A 4 1200000 CYTR Common Stock, $0.01 par value per share View
CYTR 28 June, 2012 0001550653 3098662 0000799698 Patterson Scott Bradford A 4 16000 CYTR Common Stock, $0.01 par value per share View
CYTR 27 June, 2012 0001550653 3082662 0000799698 Patterson Scott Bradford A 4 15824 CYTR Common Stock, $0.01 par value per share View
CYTR 26 June, 2012 0001550653 3066838 0000799698 Patterson Scott Bradford A 4 13000 CYTR Common Stock, $0.01 par value per share View
SymbolDatePeriodDownload XLSX File
CYTR 2021 FY Download XLSX File
CYTR 2020 FY Download XLSX File
CYTR 2019 FY Download XLSX File
CYTR 2018 FY Download XLSX File
CYTR 2017 FY Download XLSX File
CYTR 2016 FY Download XLSX File
CYTR 2015 FY Download XLSX File
CYTR 2014 FY Download XLSX File
CYTR 2013 FY Download XLSX File
CYTR 2012 FY Download XLSX File
CYTR 2011 FY Download XLSX File
CYTR 2021 Q2 Download XLSX File
CYTR 2021 Q1 Download XLSX File
CYTR 2020 Q1 Download XLSX File
CYTR 2020 Q4 Download XLSX File
CYTR 2020 Q3 Download XLSX File
CYTR 2020 Q2 Download XLSX File
CYTR 2019 Q2 Download XLSX File
CYTR 2019 Q4 Download XLSX File
CYTR 2019 Q3 Download XLSX File
CYTR 2019 Q1 Download XLSX File
CYTR 2018 Q2 Download XLSX File
CYTR 2018 Q4 Download XLSX File
CYTR 2018 Q3 Download XLSX File
CYTR 2018 Q1 Download XLSX File
CYTR 2017 Q2 Download XLSX File
CYTR 2017 Q4 Download XLSX File
CYTR 2017 Q3 Download XLSX File
CYTR 2017 Q1 Download XLSX File
CYTR 2016 Q2 Download XLSX File
CYTR 2016 Q1 Download XLSX File
CYTR 2016 Q3 Download XLSX File
CYTR 2016 Q4 Download XLSX File
CYTR 2015 Q1 Download XLSX File
CYTR 2015 Q4 Download XLSX File
CYTR 2015 Q3 Download XLSX File
CYTR 2015 Q2 Download XLSX File
CYTR 2014 Q2 Download XLSX File
CYTR 2014 Q4 Download XLSX File
CYTR 2014 Q3 Download XLSX File
CYTR 2014 Q1 Download XLSX File
CYTR 2013 Q2 Download XLSX File
CYTR 2013 Q4 Download XLSX File
CYTR 2013 Q3 Download XLSX File
CYTR 2013 Q1 Download XLSX File
CYTR 2012 Q2 Download XLSX File
CYTR 2012 Q4 Download XLSX File
CYTR 2012 Q3 Download XLSX File
CYTR 2012 Q1 Download XLSX File
CYTR 2011 Q4 Download XLSX File
CYTR 2011 Q2 Download XLSX File
CYTR 2011 Q3 Download XLSX File

Charts

Company Historical Earnings

DateSymbolEPSEPS EstimatedTimeRevenueRevenue Estimated
13 May, 2021 CYTR bmo 0 0
25 March, 2021 CYTR bmo 0 0
16 November, 2020 CYTR bmo 0 0
27 March, 2020 CYTR bmo 0 0
14 November, 2019 CYTR bmo 0 0
9 August, 2019 CYTR bmo 0 0
15 May, 2019 CYTR -0.05 -0.05 bmo 0 0
29 March, 2019 CYTR -0.07 -0.07 bmo 250000 250000
2 November, 2018 CYTR -0.1 -0.1 bmo 250000 225000
6 August, 2018 CYTR -0.1 -0.1 bmo 0 0
8 May, 2018 CYTR -0.15 -0.15 bmo 0 0
16 March, 2018 CYTR bmo 100000 0
8 November, 2017 CYTR bmo 0 0
3 August, 2017 CYTR bmo 0 0
10 May, 2017 CYTR bmo 0 0
15 March, 2017 CYTR -0.36 -0.36 bmo 100000 183333.33333333
9 November, 2016 CYTR -0.78 -0.78 bmo 100000 100000
29 July, 2016 CYTR -1.62 -1.62 bmo 100000 70370.37037037
10 May, 2016 CYTR -1.14 -1.14 bmo 0 0
11 March, 2016 CYTR -0.35 -0.35 bmo 100000 57142.857142857
3 November, 2015 CYTR -0.11 -0.11 bmo 0 0
3 August, 2015 CYTR -0.21 -0.21 bmo 0 0
1 May, 2015 CYTR -0.31 -0.31 bmo 0 0
10 March, 2015 CYTR -0.24 -0.24 bmo 100000 112500
4 November, 2014 CYTR -0.1 -0.1 bmo 0 0
6 August, 2014 CYTR -1.68 -1.68 bmo 0 0
1 May, 2014 CYTR 0.48 0.48 bmo 0 0
5 March, 2014 CYTR -4.62 -4.62 bmo 100000 21428.571428571
29 October, 2013 CYTR -1.98 -1.98 bmo 0 0
6 August, 2013 CYTR -0.66 -0.66 bmo 200000 345454.54545455
9 May, 2013 CYTR -1.38 -1.38 bmo 0 0
11 March, 2013 CYTR 1.5 1.5 bmo 100000 81333.333333333
9 November, 2012 CYTR 0.42 0.42 bmo 0 0
9 August, 2012 CYTR -3.78 -3.78 bmo 0 0
10 May, 2012 CYTR -2.94 -2.94 bmo 0 0
13 March, 2012 CYTR -1.26 -1.26 bmo 100000 116666.66666667
8 November, 2011 CYTR 0 0 bmo 150000 0
9 August, 2011 CYTR -1.26 -1.26 bmo 150000 300000
5 May, 2011 CYTR -2.52 -2.52 bmo 0 0
8 November, 2010 CYTR -1.68 -1.68 bmo 773470 930005.5952381
9 August, 2010 CYTR 0.42 0.42 bmo 8044091 38113669.261905
6 May, 2010 CYTR -0.42 -0.42 bmo 0 0
15 March, 2010 CYTR -1.26 -1.26 bmo 100000 117460.31746032
9 November, 2009 CYTR 1.68 1.68 bmo 6950000 1737500
10 August, 2009 CYTR -0.84 -0.84 bmo 960000 1840000
11 May, 2009 CYTR -1.68 -1.68 bmo 1480000 1286190.4761905
13 March, 2009 CYTR -1.68 -1.68 bmo 1430000 1430000
7 November, 2008 CYTR -5.88 -5.88 bmo 920000 328571.42857143
11 August, 2008 CYTR -2.52 -2.52 bmo 1740000 1450000
19 May, 2008 CYTR -2.94 -2.94 bmo 2180000 2180000
2 April, 2008 CYTR -2.94 -2.94 bmo 2180000 2283809.5238095
14 November, 2007 CYTR -2.1 -2.1 bmo 2050000 3787619.047619
10 August, 2007 CYTR -2.94 -2.94 bmo 2370000 2370000
10 May, 2007 CYTR -2.52 -2.52 bmo 1560000 1560000
3 April, 2007 CYTR -2.52 -2.52 bmo 1560000 1300000
22 May, 2006 CYTR -2.94 -2.94 bmo 60000 51428.571428571
31 March, 2006 CYTR -2.52 -2.52 bmo 170000 198333.33333333
15 November, 2005 CYTR -2.52 -2.52 bmo 10000 12500
15 August, 2005 CYTR -3.36 -3.36 bmo 1500 1312.5
16 May, 2005 CYTR -2.94 -2.94 bmo 1500 1714.2857142857
31 March, 2005 CYTR -6.3 -6.3 bmo 100000 43333.333333333
3 November, 2004 CYTR -3.36 -3.36 bmo 328164 389694.75
18 August, 2004 CYTR -5.04 -5.04 bmo 230000 230000
17 May, 2004 CYTR -3.78 -3.78 bmo 100000 55555.555555556
14 May, 2004 CYTR -3.78 -3.78 bmo 100000 55555.555555556
23 October, 1997 CYTR -7.56 -7.56 bmo 720000 560000
22 July, 1997 CYTR -13.02 -13.02 bmo 550000 212903.22580645
21 February, 1995 CYTR -11.76 -11.76 bmo 0 0
21 October, 1994 CYTR -10.08 -10.08 bmo 0 0
22 July, 1994 CYTR -10.08 -10.08 bmo 0 0
18 February, 1994 CYTR -10.08 -10.08 bmo 0 0
19 October, 1993 CYTR -5.04 -5.04 bmo 0 0
20 July, 1993 CYTR -1.68 -1.68 bmo 0 0
27 April, 1993 CYTR 0 0 bmo 0 0
18 February, 1993 CYTR -1.68 -1.68 bmo 0 0

Company Profile

Company Name CytRx Corporation
Symbol CYTR
Currency USD
Price 3.2101
Exchange Name Nasdaq Capital Market (NASDAQ)
Industry Biotechnology
CEO Mr. Steven Kriegsman
Sector Healthcare
Country US
Full Time Employees 4
Phone 13108265648
Address 11726 San Vicente Blvd Ste 650
City Los Angeles
State CALIFORNIA
Zip 90049
>